Form 4: Gilead SVP Burkhart Receives Equity Grants

Erin Burkhart, SVP of Controllership at Gilead Sciences, Inc., was granted 2,355 restricted stock units and 5,455 non-qualified stock options.

Summary

• Erin Burkhart, SVP, Controllership of Gilead Sciences, Inc. (GILD), reported the acquisition of equity awards.
• On March 10, 2026, Burkhart was granted 2,355 Restricted Stock Units (RSUs), each representing the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• These RSUs have a 4-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining 6.25% vesting quarterly thereafter until fully vested.
• Following this transaction, Burkhart beneficially owns 11,245 Restricted Stock Units.
• On March 10, 2026, Burkhart was also granted 5,455 Non-qualified Stock Options with an exercise price of $148.56.
• These stock options also have a 4-year vesting schedule, with 25% vesting on the first anniversary of the grant date and the remaining 6.25% vesting quarterly thereafter until fully vested.
• The stock options have an expiration date of March 10, 2036.
• Following this transaction, Burkhart beneficially owns 5,455 Non-qualified Stock Options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with long-term company performance and shareholder interests.

Positives

• The grants of Restricted Stock Units and Non-qualified Stock Options align the interests of SVP Erin Burkhart with those of shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs and stock options, extending over four years, promote retention of key management personnel.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units and stock options, are standard components of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to incentivize long-term performance and align executive interests with shareholder value creation, a common practice among large-cap pharmaceutical companies like Gilead Sciences.

Comparison to Industry Standards

• The 4-year vesting schedule for both RSUs and stock options is a common practice in the pharmaceutical and biotech sectors, comparable to companies like Amgen (AMGN) or Bristol Myers Squibb (BMY), which often use similar multi-year vesting periods to ensure executive retention and long-term commitment.
• The grant of both RSUs and stock options is a diversified approach to equity compensation, frequently observed in the industry to balance immediate value (RSUs) with future upside potential (options).

Stakeholder Impact

• Shareholders: The grants align executive incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• The Restricted Stock Units will vest over a 4-year schedule, with 25% vesting on March 10, 2027, and 6.25% quarterly thereafter.
• The Non-qualified Stock Options will vest over a 4-year schedule, with 25% vesting on March 10, 2027, and 6.25% quarterly thereafter.

Key Dates

Recommendation

This Form 4 filing reports routine executive equity grants and does not contain information that would significantly alter the fundamental investment thesis for Gilead Sciences. The grants are standard compensation and do not indicate any material change in the company's operational or financial outlook, thus a 'hold' recommendation is appropriate.

Keywords

Gilead Sciences, GILD, Erin Burkhart, SVP Controllership, SEC Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Insider Transaction